All In Biotech

Drug Trial Radar · NCT01827605

A Phase III Multicenter, Randomized Study Comparing RIT Vs ASCT in Patients With Relapsed/Refractory (FL)

A Phase III Multicenter,Randomized Study Comparing Consolidation With 90yttrium-Labeled Ibritumomab Tiuxetan (Zevalin®) Radioimmunotherapy Vs Autologous Stem Cell Transplantation (ASCT) in Patients With Relapsed/Refractory Follicular Lymphoma (FL) Aged 18-65 Years

Last checked: Nov 20, 2026Latest source record: Sep 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 159 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

159

Actual

Start

Jan 2012

Primary completion

Oct 2019

Study completion Jan 2024

Sponsor

Lead sponsor
Fondazione Italiana Linfomi - ETSAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Apr 9, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase III, multicenter, open-label, randomized and controlled study to compare the efficacy of a consolidation therapy with RIT versus ASCT in patients with FL in CR or PR after second or third line chemotherapy supplemented with rituximab.

Conditions

  • Relapsed Follicular Lymphoma

Interventions

  • ZEVALINOther

    Infusion of 90Y Ibritumomab Tiuxetan if the patient has less than 25% BM infiltration at the pre-consolidation restaging (0.4 mCi/kg if platelets ≥150,000/mmc, 0.3 mCi/kg if platelets are between 100.000 and 150,000/mmc).

  • BEAMDrug

    BEAM REGIMEN day -6 Carmustine\* 300 mg/ m2 i.v. in 250ml dextrose 5% solution from day -5 to day -2 Cytarabine 200 mg/m2 i.v. every 12 hours in 250 ml dextrose 5% solution, 250 ml/hr Etoposide 100 mg/m2 i.v. every 12 hours in 250 ml dextrose 5% solution, 250 ml/hr day -1 Melphalan 140 mg/m2 i.v. in 100ml saline solution in 200 ml/hr day 0 UReinfusion of autologous stem cells following this rules: 1. Patient collecting ≥6x106 CD34+ cells/kg use \>4x106 CD34+ cells/kg for ASCT and keep \>2x106 CD34+ cells/kg for back up; 2. Patient collecting 4-6x106 CD34+ cells/kg use \>2x106 CD34+ cells/kg for ASCT and keep \>2x106 CD34+ cells/kg for back up; 3. Patient collecting 2-4x106 CD34+ cells/kg use all CD34+ cells for ASCT and keep no back up. day 2 Filgrastim or Lenograstim 5μg/Kg s.c. until ANC \> 1500/mmc

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression Free Survival from randomization (rPFS)Time frame: 36 months

Locations

38 sites in 1 country. Site status is shown where the registry gives one.

  • Presidio Ospedaliero A.Perrino - Divisione di Ematologia

    Brindisi, Italy

  • Divisione di Ematologia Osp. Businco

    Cagliari, Italy

  • IRCC Onco-Ematologia

    Candiolo, Italy

  • Ospedale Ferrarotto

    Catania, Italy

  • Policlinico Careggi Clinica Ematologica

    Florence, Italy

  • A O Papardo

    Messina, Italy

  • IRCCS San Raffaele Unità di Chemioterapia

    Milan, Italy

  • Policlinico di Modena - Università degli studi

    Modena, Italy

  • Istituto Pascale Oncoematologia

    Naples, Italy

  • Ospedale S. Francesco

    Nuoro, Italy

  • Ospedale Santa Maria della Misericordia

    Perugia, Italy

  • Ospedale Santo Spirito Dipartimento di Ematologia

    Pescara, Italy

  • Ausl Ravenna

    Ravenna, Italy

  • Univeristà La Sapienza

    Roma, Italy

  • SC Ematologia Città della salute e della scienza di Torino

    Torino, Italy

  • Filippo Gherlizoni

    Treviso, Italy

  • UO Ematologia Osp. Cardinale Panico

    Tricase, Italy

  • Clinica di Ematologia - A.O.U. S. Maria di Udine

    Udine, Italy

  • A.O. SS. Antonio e Biagio e C. Arrigo

    Alessandria, Alessandria, Italy

  • Clinica di ematologia AOU Umberto I Ospedali Riuniti

    Ancona, Ancona, Italy

  • Ematologia con Trapianto Policlinico Universitario Consorziale

    Bari, Bari, Italy

  • Spedali Civili

    Brescia, Brescia, Italy

  • A.O.U. San Martino

    Genova, GE, Italy

  • Azienda Ospedaliera V. Cervello

    Palermo, Italy, Italy

  • A.O. Niguarda

    Milan, MI, Italy

  • Ematologia e Trapianto IRCCS, Istituto Nazionale dei Tumori

    Milan, Milano, Italy

  • Ematologia, A.O. San Gerardo

    Monza, Milano, Italy

  • SCDU Ematologia - Università del Piemonte Orientale

    Novara, Novara, Italy

  • U.O. Complessa di Ematologia Ospedale di Parma

    Parma, Parma, Italy

  • Ematologia Policlinico San Matteo

    Pavia, Pavia, Italy

  • Unità Ematologia Ospedale Civile di Piacenza

    Piacenza, Piacenza, Italy

  • IRCCS-Centro di riferimento oncologico UO di ematologia e Trapianto Cellule Staminali

    Rionero in Vulture, Potenza, Italy

  • Azienda Ospedaliera "Bianchi Melacrino Morelli"

    Reggio Calabria, RC, Italy

  • SC Ematologia AO Santa Maria Nuova IRCCS

    Reggio Emilia, Reggio Emilia, Italy

  • Presidio Ospedaliero "A. Tortora"

    Pagani, SA, Italy

  • Emat Univ - Città della salute e della scienza di Torino

    Torino, TO, Italy

  • Ospedale San Bortolo

    Vicenza, VI, Italy

  • Ospedale Policlinico G.B. Rossi (Borgo Roma) Di Verona

    Verona, VR, Italy

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.